Josh Reynolds has extensive experience in the pharmaceutical and biotechnology sectors, particularly in oncology. At Seattle Genetics, from September 2019 to September 2025, Josh served as Division Manager for Tucatinib (TUKYSA) in the Great Lakes region, facilitating a successful product launch and overseeing the label indication for mCRC. Prior to this role, Josh was a Senior Oncology Account Manager, where Josh launched Adcetris (Brentuximab Vedotin) and received multiple awards for performance. Currently, Josh serves as Regional Business Director for Celcuity since November 2025. Previous positions include Oncology Account Specialist at Eisai, where Josh launched Halaven (Eribulin Mesylate), and various roles at EKR Therapeutics and APP Pharmaceuticals, focusing on institutional sales and contracting. Josh holds an MBA in Management from Indiana University and a Bachelor’s degree in Finance from the Kelley School of Business at Indiana University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices